
International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
WSMCDD-2025
GSMCDD-2025
Conferences Published ↓
RBS:RH-COVID-19 (2023)
ICMRS'23
PIPRDA-2023
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 7 Issue 2
March-April 2025
Indexing Partners



















Comparative Efficacy of Antidepressants in the Treatment of Major Depressive Disorder (MDD) in Adult’s
Author(s) | Dr. Vidhu Arora, Amala Maria Saji, Dhruvil A Kheni, Sayed Ali Sajad |
---|---|
Country | India |
Abstract | Major depressive disorder (MDD) is a debilitating mental health condition with a high prevalence among adults globally. Despite the availability of numerous antidepressant medications, the comparative efficacy and tolerability of these treatments remain unclear. This systematic review aims to analyze and compare the efficacy and safety profiles of antidepressants, including SSRIs, SNRIs, TCAs, and atypical antidepressants, in adult populations diagnosed with MDD. A thorough literature search spanning PubMed, EMBASE, PsycINFO, and the Cochrane Library was conducted, identifying randomized controlled trials (RCTs) published between January 2000 and December 2024. Key performance metrics, including response rates (≥50% symptom improvement), remission rates, and adverse event frequencies, were evaluated. Statistical analyses using random-effects models were performed to synthesize data from included studies. Preliminary findings indicate that while SSRIs and SNRIs demonstrate comparable efficacy in achieving symptom remission, SNRIs offer slightly higher response rates in severe MDD cases. Atypical antidepressants exhibit diverse tolerability profiles, with some showing lower rates of treatment-emergent adverse events. TCAs, although effective, are often associated with higher dropout rates due to their safety concerns. Additionally, patient-specific factors such as baseline severity, comorbidities, and prior treatment history emerged as significant moderators of treatment outcomes. This review underscores the importance of personalized treatment strategies in managing MDD and highlights key areas for future research, including head-to-head comparisons and the integration of biomarkers for treatment optimization. Findings are expected to provide valuable insights for clinicians in tailoring treatment regimens to improve patient outcomes. |
Keywords | Major depressive disorder, antidepressants, efficacy, comparative study, adults |
Field | Biology |
Published In | Volume 7, Issue 2, March-April 2025 |
Published On | 2025-03-26 |
DOI | https://doi.org/10.36948/ijfmr.2025.v07i02.38971 |
Short DOI | https://doi.org/g8936s |
Share this

E-ISSN 2582-2160

CrossRef DOI is assigned to each research paper published in our journal.
IJFMR DOI prefix is
10.36948/ijfmr
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.
